
    
      This study has 2 parts: Part 1 is a placebo-controlled, single ascending dose study where
      male only subjects will be residential for 5-8 days (Part 1 will also include an open-label,
      food effect section); and Part 2 is a placebo-controlled, randomized, 2-way crossover,
      multiple ascending dose study where male and female subjects will be residential for 14-17
      days for each treatment period. There will be a washout period between the 2 periods in Part
      2.
    
  